Video

Dr Timothy Murphy: Strong Communication Is Necessary for Practices Stocking Multiple Biosimilars

Author(s):

With multiple biosimilars approved for a reference product and different payers preferring particular products, communication between the clinical pharmacy team and the managed care team is crucial, said Timothy Murphy, MD, FACP, medical oncologist/hematologist with Rocky Mountain Cancer Centers.

With multiple biosimilars approved for a reference product and different payers preferring particular products, communication between the clinical pharmacy team and the managed care team is crucial, said Timothy Murphy, MD, FACP, medical oncologist/hematologist with Rocky Mountain Cancer Centers.

Transcript

How are community oncology practices handling the challenge of stocking multiple biosimilars for the same reference product and balancing the needs of various payers?

Fortunately, those issues play to the power of community oncology, and particularly Rocky Mountain Cancer Centers. We have a strong clinical pharmacy team—they work very closely with our managed care team. To your point, some payers are now preferring a particular product vs another. In the old days, we could have one type of medication in that class, but now we're going to have to keep inventory with multiple.

That takes a strong pharmacy-led team. It takes strong education on the pharmacy techs. It takes strong leadership from the managed care team. That communication piece is vital. Once the physicians got buy-in—they trusted the process—I think we're well positioned to handle this transformation, which is happening in real time.

Related Videos
Robin Glasco, MBA
Joshua K. Sabari, MD, NYU Langone Perlmutter Cancer Center
Kara Kelly, MD, chair of pediatrics, Roswell Park Oishei Children's Cancer and Blood Disorders Program
1 KOL is featured in this series.
Hans Lee, MD
Screenshot of an interview with Amir Ali, PharmD, BCOP
Mansi Shah, MD, assistant professor, Rutgers Cancer Institute of New Jersey
1 expert in this video
1 expert in this video
 Alvaro Alencar, MD, associate professor of clinical medicine, chief medical officer, University of Miami Sylvester Comprehensive Cancer Center
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo